Cover image

Cover: Courtesy of Christopher M. Dooley, Wellcome Trust Sanger Institute.
This issue

- Open Access
Joint development recovery on resumption of embryonic movement following paralysis
Rebecca A. Rolfe, David Scanlon O'Callaghan, Paula Murphy - Open Access
Hnf1b haploinsufficiency differentially affects developmental target genes in a new renal cysts and diabetes mouse model
Leticia L. Niborski, Mélanie Paces-Fessy, Pierbruno Ricci, Adeline Bourgeois, Pedro Magalhães, Maria Kuzma-Kuzniarska, Celine Lesaulnier, Martin Rezko, Edwige Declercq, Petra Zürbig, Alain Doucet, Muriel Umbhauer, Silvia Cereghini - Open Access
An Fgfr3-activating mutation in immature osteoblasts affects the appendicular and craniofacial skeleton
Martin Biosse Duplan, Emilie Dambroise, Valentin Estibals, Joelle Veziers, Jérome Guicheux, Laurence Legeai-Mallet - Open Access
Selective disruption of trigeminal sensory neurogenesis and differentiation in a mouse model of 22q11.2 deletion syndrome
Beverly A. Karpinski, Thomas M. Maynard, Corey A. Bryan, Gelila Yitsege, Anelia Horvath, Norman H. Lee, Sally A. Moody, Anthony-Samuel LaMantia - Open Access
Sex differences in insulin resistance but not peripheral neuropathy in a diet-induced prediabetes mouse model
Sarah E. Elzinga, Masha G. Savelieff, Phillipe D. O'Brien, Faye E. Mendelson, John M. Hayes, Eva L. Feldman
Other journals from The Company of Biologists
DMM and COVID-19
We are aware that the COVID-19 pandemic is having an unprecedented impact on researchers worldwide. The Editors of all The Company of Biologists’ journals have been considering ways in which we can alleviate concerns that members of our community may have around publishing activities during this time. Read about the actions we are taking at this time.
Please don’t hesitate to contact the Editorial Office if you have any questions or concerns.
The twin pillars of Disease Models & Mechanisms
In her first Editorial as Editor-in-Chief, Liz Patton sets out her vision and priorities for DMM focusing on four thematic challenges: mechanisms of disease, innovative technologies, disease progression through time and therapy.
Extended deadline - The RAS Pathway: Diseases, Therapeutics and Beyond
Our upcoming special issue is welcoming submissions until 3 May 2021. Guest-edited by Donita Brady (Perelman School of Medicine at the University of Pennsylvania, USA) and Arvin Dar (Icahn School of Medicine at Mount Sinai, USA), the issue will focus on the targeting the RAS pathway.
Find out more about the issue and how to submit your manuscript.
Perspective - Modelling the developmental origins of paediatric cancer to improve patient outcomes
James Amatruda authors our first Perspective, discussing some of the key challenges in paediatric cancer from his perspective as a physician-scientist.
A muscle growth-promoting treatment based on the attenuation of activin/myostatin signalling results in long-term testicular abnormalities
In this issue’s Editor’s choice, Ketan Patel and colleagues describe how even brief exposure to muscle-growth-promoting treatments exerts a long-term detrimental effect on the testes, and test promising therapeutics to mitigate this side-effect.